Sugi Predict

Sugi Predict / Compounds / SCHEMBL2647154

SCHEMBL2647154

SCHEMBL2647154

CS(=O)(=O)O[C@H]1C[C@@H](OCc2ccccc2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.43
▸ CTSB P07858 1/20 0.43
▸ CTSK P43235 1/20 0.43
▸ OPRM1 P35372 2/20 0.42
▸ OPRL1 P41146 2/20 0.42
▸ NAAA Q02083 2/20 0.40
▸ TMEM97 Q5BJF2 1/20 0.40
▸ CARM1 Q86X55 1/20 0.40
▸ PRMT6 Q96LA8 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ PRMT8 Q9NR22 1/20 0.40
▸ HRH3 Q9Y5N1 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA2 P00918 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ DPP4 P27487 1/20 0.39
▸ ACACB O00763 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ AR P10275 1/20 0.38
▸ HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17443117 1.00 CTSL (0.43) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL428528 1.00 CTSL (0.43) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL21570696 0.94 CTSL (0.41) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL4136007 0.91 OPRM1 (0.43) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL25525463 0.91 OPRM1 (0.43) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL717952 0.87 OPRM1 (0.49) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL4442781 0.86 CTSL (0.42) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL445076 0.84 CTSL (0.43) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL9895268 0.84 CTSL (0.38) CTSLCTSBCTSKOPRM1OPRL1
SCHEMBL9895267 0.84 CTSL (0.38) CTSLCTSBCTSKOPRM1OPRL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117940438-A Heterocyclic compounds as MAP4K1 inhibitors 缆图药品公司 2024-04-26 — — CN disclosed
US-11958837-B2 Quinazolinones as PARP14 inhibitors RIBON THERAPEUTICS, INC. (US) 2024-04-16 — — US disclosed
EP-4212515-A1 QUINAZOLINONES AS PARP14 INHIBITORS Ribon Therapeutics Inc. (US) 2023-07-19 — — EP disclosed
US-11612606-B2 8-aminoisoquinoline compounds and uses thereof GENENTECH, INC. (US) 2023-03-28 — — US disclosed
EP-3728207-B1 QUINAZOLINONES AS PARP14 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-02-01 — — EP disclosed
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2023-01-19 — — US disclosed
US-11518761-B2 CDPK1 inhibitors, compositions, and methods related thereto Vyera Pharmaceuticals, LLC (US) 2022-12-06 — — US disclosed
WO-2022109580-A1 INHIBITION OF TYK2 DEPENDENT SIGNALING PATHWAYS JANSSEN PHARMACEUTICA NV (BE) 2022-05-27 — — WO disclosed
US-20210347780-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC 2021-11-11 — — US disclosed
EP-3860980-A1 8-AMINOISOQUINOLINE COMPOUNDS AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2021-08-11 — — EP disclosed
US-20190194174-A1 QUINAZOLINONES AS PARP14 INHIBITORS ABBVIE BIOTECHNOLOGY LTD (BM) 2019-06-27 — — US disclosed
WO-2019036001-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2019-02-21 — — WO disclosed
WO-2019036001-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO Vyera Pharmaceuticals, LLC (US) 2019-02-21 — — WO disclosed
WO-2016009296-A1 N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2016-01-21 — — WO disclosed
WO-2016009296-A1 N-ACYLPIPERIDINE ETHER TROPOMYOSIN-RELATED KINASE INHIBITORS PFIZER INC. (US) 2016-01-21 — — WO disclosed
US-6828322-B2 Substituted 1,2, 4-triazolo(4,3-b)pyridazine derivatives; anxiolytic; anticonvulsant; antimigraine MERCK SHARP & DOHME LTD. 2004-12-07 — — US disclosed
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors CARLING WILLIAM ROBERT (GB) 2004-04-01 — — US disclosed
US-6579875-B1 Treatment of anxiety and convulsions; 7-cyclobutyl-3-(2,6-difluorophenyl)-6-(2-methyl-2H-1,2,4-triazol-3 -ylmethyoxy)-1,2,4-triazolo(4,3-b) pyridazine MERCK SHARP & DOHME LIMITED 2003-06-17 — — US disclosed
EP-1049696-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LTD. (GB) 2000-11-08 — — EP disclosed
WO-1999037644-A1 TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME LIMITED (GB) 1999-07-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11958837-B2 Quinazolinones as PARP14 inhibitors PARP14, PARP15, PARP11 CTSL 2188/4885CTSB 1465/4885CTSK 1305/4885
US-20040063714-A1 Triazolo-pyridazine derivatives as ligands for GABA receptors GABRA3, GABBR1, GABRA2 CTSL 4658/4885CTSB 4384/4885CTSK 4387/4885
US-20210347780-A1 CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO CAMKK1, CAMK1, CAMKK2 CTSL 904/4885CTSB 1303/4885CTSK 235/4885
US-11518761-B2 CDPK1 inhibitors, compositions, and methods related thereto CAMKK1, CAMK1, CAMKK2 CTSL 904/4885CTSB 1303/4885CTSK 235/4885
US-20230018702-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 CTSL 2188/4885CTSB 1465/4885CTSK 1305/4885
US-20190194174-A1 QUINAZOLINONES AS PARP14 INHIBITORS PARP14, PARP15, PARP11 CTSL 2188/4885CTSB 1465/4885CTSK 1305/4885
US-11612606-B2 8-aminoisoquinoline compounds and uses thereof PHKG1, MAP4K5, HIPK1 CTSL 3651/4885CTSB 3569/4885CTSK 492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.